找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cell Death Signaling in Cancer Biology and Treatment; Daniel E. Johnson Book 2013 Springer Science+Business Media New York 2013 Cancer.Can

[复制链接]
楼主: Fillmore
发表于 2025-3-26 21:27:34 | 显示全部楼层
Book 2013ic modifications, DNA repair pathways, and protein chaperones, as a means of provoking tumor cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.
发表于 2025-3-27 04:25:34 | 显示全部楼层
Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members,opment and application of three small molecule inhibitors (ABT-737, ABT-263, GX15-070), with a particular emphasis on progress that has been made in the evaluation of these compounds in preclinical in vivo models and clinical trials.
发表于 2025-3-27 05:44:46 | 显示全部楼层
Book 2013 and Treatment. is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell de
发表于 2025-3-27 12:28:35 | 显示全部楼层
2625-2902 or cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.978-1-4939-0107-4978-1-4614-5847-0Series ISSN 2625-2902 Series E-ISSN 2625-2899
发表于 2025-3-27 13:53:12 | 显示全部楼层
发表于 2025-3-27 18:55:11 | 显示全部楼层
Assessing IEQ Performance in BuildingsThis has become highly relevant as it is suggested that most cancer cells are likely to be defective in some aspect of DNA repair. Herein, we describe the molecular pathways that participate in the repair of DNA damage induced by radiation- and chemotherapeutics and discuss strategies that are being
发表于 2025-3-28 01:00:34 | 显示全部楼层
Acids and Additives Used in Acidizingable target for cancer treatment. This idea has been validated from benchtop to bedside. In 2003, the first proteasome inhibitor anticancer drug, bortezomib, was approved in the United States for the treatment of multiple myeloma and mantle cell lymphoma. While bortezomib achieved great success in c
发表于 2025-3-28 02:23:29 | 显示全部楼层
Arrivals, Departures and Returnsle environment for the generation of anti-tumor immunity. Activation of immune-mediated tumor cell death by chemotherapy opens the door to the possibility of novel treatment strategies combining standard chemotherapy with immunotherapy agents aimed at enhancing such responses. Preclinical studies an
发表于 2025-3-28 07:08:21 | 显示全部楼层
发表于 2025-3-28 11:40:31 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-26 19:55
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表